REBECCA KOLBAS: Open Payments
NPI 1386159796 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,045 in 43 payments from 25 companies in 2025. Trend: 2023 $457 · 2024 $1,151 · 2025 $1,045
Food & beverage: $1,045
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 5 | $137 |
| Daiichi Sankyo Inc. | 3 | $68 |
| Gilead Sciences, Inc. | 3 | $67 |
| Merck Sharp & Dohme LLC | 2 | $65 |
| GlaxoSmithKline, LLC. | 3 | $61 |
| Janssen Biotech, Inc. | 3 | $60 |
| BeOne Medicines USA, Inc. | 2 | $55 |
| Legend Biotech USA Inc. | 2 | $48 |
| Adaptive Biotechnologies Corporation | 2 | $48 |
| ABBVIE INC. | 2 | $44 |
Products named: Enhertu, Trodelvy, KEYTRUDA, BRUKINSA, CARVYKTI, clonoSEQ, OJJAARA, EPKINLY.
Industry payments across GA — which companies pay providers there.
